Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase NA 2Phase 2/3 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 15Lymphoid 15Sarcoma 2Gynecologic 2Genitourinary 2Myeloid 1Classical hematology 1Breast 1

Conditions

Gestational Trophoblastic Disease 2Drug-Related Side Effects and Adverse Reactions 1

Interventions

Paclitaxel 12Carboplatin 11Cisplatin 9Letrozole 6Drug Therapy 6liposomal doxorubicin 5Megestrol Acetate 4Bevacizumab 4spartalizumab 3Topotecan 3Taxes 3Medroxyprogesterone Acetate 3olaparib 2niraparib 2atezolizumab 2Methotrexate 2Magnetic Resonance Spectroscopy 2Imiquimod 2Hyperthermic Intraperitoneal Chemotherapy 2Gonadotropin-Releasing Hormone 2Gemcitabine 2Doxorubicin 21-dodecylpyridoxal 2trametinib 1sintilimab 1saracatinib 1ricin A-GnRH conjugate 1pertuzumab 1pembrolizumab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Methotrexate × Gynecologic × Clear all
NCT03885388 2019-03-21

Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma (GTN) Patients With Score of 5-6

Women's Hospital School Of Medicine Zhejiang University

Phase 2/3 Unknown
300 enrolled
Gynecologic

Gestational Trophoblastic Disease, Drug-Related Side Effects and Adverse Reactions

NCT02606539 2017-03-22

SVCGTN

Mansoura University

Phase 2/3 Unknown
20 enrolled
Gynecologic

Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡